Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients.
Lim EHT, Vlaar APJ, de Bruin S, Rückinger S, Thielert C, Habel M, Guo R, Burnett BP, Dickinson J, Brouwer MC, Riedemann NC, van de Beek D; PANAMO study group. Lim EHT, et al. Among authors: guo r. Intensive Care Med Exp. 2023 Jun 19;11(1):37. doi: 10.1186/s40635-023-00520-8. Intensive Care Med Exp. 2023. PMID: 37332066 Free PMC article.
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, Lim EHT, Brouwer MC, Tuinman PR, Saraiva JFK, Marx G, Lobo SM, Boldo R, Simon-Campos JA, Cornet AD, Grebenyuk A, Engelbrecht JM, Mukansi M, Jorens PG, Zerbib R, Rückinger S, Pilz K, Guo R, van de Beek D, Riedemann NC; PANAMO study group. Vlaar APJ, et al. Among authors: guo r. Lancet Respir Med. 2022 Dec;10(12):1137-1146. doi: 10.1016/S2213-2600(22)00297-1. Epub 2022 Sep 7. Lancet Respir Med. 2022. PMID: 36087611 Free PMC article. Clinical Trial.
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D. Vlaar APJ, et al. Among authors: guo rf. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28. Lancet Rheumatol. 2020. PMID: 33015643 Free PMC article.
Role of C5a-C5aR interaction in sepsis.
Guo RF, Riedemann NC, Ward PA. Guo RF, et al. Shock. 2004 Jan;21(1):1-7. doi: 10.1097/01.shk.0000105502.75189.5e. Shock. 2004. PMID: 14676676 Review.
Novel strategies for the treatment of sepsis.
Riedemann NC, Guo RF, Ward PA. Riedemann NC, et al. Nat Med. 2003 May;9(5):517-24. doi: 10.1038/nm0503-517. Nat Med. 2003. PMID: 12724763 Review.
The enigma of sepsis.
Riedemann NC, Guo RF, Ward PA. Riedemann NC, et al. J Clin Invest. 2003 Aug;112(4):460-7. doi: 10.1172/JCI19523. J Clin Invest. 2003. PMID: 12925683 Free PMC article. Review.
C5a receptor and thymocyte apoptosis in sepsis.
Riedemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, Padgaonkar V, Zetoune FS, Ward PA. Riedemann NC, et al. FASEB J. 2002 Jun;16(8):887-8. doi: 10.1096/fj.02-0033fje. Epub 2002 Apr 23. FASEB J. 2002. PMID: 12039868 Free article.
7,173 results